Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
August 31st 2023Experts discuss the recently FDA-approved nirsevimab for the prevention of Respiratory Syncytial Virus (RSV) for late-preterm and term infants, highlighting a recent study on the safety and efficacy of nirsevimab.